Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8341. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study

A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone M D, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di (...) Filippo F, Cognetti F, Botti C, Roselli M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of carcinoembryonic antigen (CEA) for monitoring breast cancer at three different stages. The three stages were at the time

NHS Economic Evaluation Database.2001

8342. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer

Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer Guyatt G H, Bethune D C, Deslauriers J, Inculet R I, Lefcoe M S, Winton T L, Shamji F M, Todd T R, Walter S D, Cook D J, Buckingham L A, Duchesne J S, Khan H, Troyan S M, Bugden C, Yazer M, Bedard P, Carrier G (...) , Ferland S, Fournier B, Miller J D, Bennett W F, McDonald E, Torbiak R P, Marryatt G, et al Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The comparison of limited versus full investigation of extrathoracic metastatic disease

NHS Economic Evaluation Database.2001

8345. Brachytherapy in early localized prostate cancer

Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Comite d' Evaluation et de Diffusion des Innovations Technologiques Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Comite d' Evaluation et de Diffusion des Innovations Technologiques (...) . Brachytherapy in early localized prostate cancer. Paris: Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT). 01.06. 2001 Authors' objectives This report aims to assess the wider application of brachytherapy in the treatment of forms of early localized prostate cancer. Authors' conclusions The CEDIT is of the opinion that there are too many reservations regarding brachytherapy as a treatment for early localized prostate cancer in terms of exact indications, methodology, effectiveness

Health Technology Assessment (HTA) Database.2001

8346. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, Larvin M, Radstone D (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, Larvin M, Radstone D. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technology Assessment 2001; 5(24): 1-79 Authors' objectives

Health Technology Assessment (HTA) Database.2001

8347. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer Forbes C, Shirran L, Bagnall A M, Duffy S, ter Riet G Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Forbes C, Shirran L, Bagnall A M, Duffy S, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technology Assessment 2001; 5(28): 1-109 Authors' objectives To examine the clinical effectiveness and cost-effectiveness of oral and intravenous topotecan (Hycamtin(R), SmithKline Beecham, UK) for the treatment

Health Technology Assessment (HTA) Database.2001

8348. A population-based cohort study of surveillance mammography after treatment of primary breast cancer

A population-based cohort study of surveillance mammography after treatment of primary breast cancer A population-based cohort study of surveillance mammography after treatment of primary breast cancer A population-based cohort study of surveillance mammography after treatment of primary breast cancer Paszat L, Grunfeld E, van Walraven C, Coyle D, Sawka C, Yun J, McGahan L, Noorani H Z Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Paszat L, Grunfeld E, van Walraven C, Coyle D, Sawka C, Yun J, McGahan L, Noorani H Z. A population-based cohort study of surveillance mammography after treatment of primary breast cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 26 Authors' objectives This report presents

Health Technology Assessment (HTA) Database.2001

8349. Guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer)

Guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer) Guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer) Guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer) National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer) London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 23. 2001 Authors' objectives To provide guidance on the use of temozolamide for the treatment of recurrent malignant glioma (brain cancer). Authors' conclusions Guidance 1.1 Patients with recurrent malignant glioma (brain cancer) who have failed

Health Technology Assessment (HTA) Database.2001

8350. Chemotherapy for cancer

Chemotherapy for cancer Chemotherapy for cancer Chemotherapy for cancer Swedish Council on Technology Assessment in Health Care (SBU) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Swedish Council on Technology Assessment in Health Care (SBU). Chemotherapy for cancer. Stockholm: Swedish Council on Technology Assessment in Health Care (...) (SBU) 2001: 235 Authors' objectives This report aims to determine whether the scientific literature supports the use of chemotherapy to treat several important cancer types and to assess the weight of the evidence. Another aim is to determine, through a survey of current practices, whether the use of chemotherapy complies with the scientific evidence presented in the literature. Authors' conclusions Chemotherapy plays a role in both curative and palliative treatment in patients with the types

Health Technology Assessment (HTA) Database.2001

8351. Clinical practice guidelines for the management of early breast cancer

Clinical practice guidelines for the management of early breast cancer

Cancer Australia2001

8354. Presymptomatic diagnosis of hereditary colorectal cancer

Presymptomatic diagnosis of hereditary colorectal cancer Presymptomatic diagnosis of hereditary colorectal cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Presymptomatic diagnosis of hereditary colorectal cancer Share: Reading time approx. 2 minutes This document was published more than 2 years ago. The nature of the evidence may have (...) changed. Findings by SBU Alert This is a translation of version 1, published on February 2, 2000. The latest version of this report is not available in English. People with a hereditary disposition for colorectal cancer are at high risk for developing cancer during their lifetime. Methods are available both to determine whether such a predisposition exists and to detect early stages of cancer. Given this information, patients can be screened via regular examination of the colon (coloscopy) and in some

Swedish Council on Technology Assessement2001

8355. Photodynamic therapy for skin cancer

Photodynamic therapy for skin cancer Photodynamic therapy for skin cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Photodynamic therapy for skin cancer Share: Reading time approx. 3 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert Version: 1 Method and Target Group (...) The number of new cases of skin cancer has been increasing for several years. The three different types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. Photodynamic therapy (PDT) is a new method for treating extended preliminary stages of squamous cell carcinoma, ie, actinic keratosis, and superficial forms of basal cell carcinoma. In PDT, an ointment containing delta aminolevulinic acid (ALA) is applied to the skin. This agent is allowed to work for 4 to 6 hours

Swedish Council on Technology Assessement2001

8356. Trastuzumab (herceptin) for metastasized breast cancer</a>

Trastuzumab (herceptin) for metastasized breast cancer Trastuzumab (herceptin) for metastasized breast cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Trastuzumab (herceptin) for metastasized breast cancer Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed (...) . Findings by SBU Alert Version: 1 Method and target group Trastuzumab (Herceptin) is a new drug for treating patients with metastasized breast cancer. It is prescribed with the aim to inhibit growth of cancer cells that demonstrate a high prevalence (overexpression) of a particular protein on the cell surface, which can be found in cancer cells from approximately 25 percent of all new cases of breast cancer in women. The drug is delivered via infusion once per week. The target group includes patients

Swedish Council on Technology Assessement2001

8357. Stem cell transplantation for metastasized kidney cancer

Stem cell transplantation for metastasized kidney cancer Stem cell transplantation for metastasized kidney cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Stem cell transplantation for metastasized kidney cancer Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have (...) changed. Findings by SBU Alert Version: 1 Technology and target group Transplantation of blood-forming stem cells, where the donor is either a sibling or an unrelated person with matching tissue, is an established treatment method, eg, for malignant blood diseases. In the new host, stem cells are capable of restoring their bone marrow function and creating a functioning immune defense. Some donor cells are able to kill malignant cells via the so-called Graft-versus-Tumor (GvT) effect. By transplanting

Swedish Council on Technology Assessement2001

8358. Chemotherapy for cancer</a>

Chemotherapy for cancer Chemotherapy for cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Chemotherapy for cancer Share: Reading time approx. 25 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Assessment Objectives This report aims to determine whether the scientific literature (...) supports the use of chemotherapy to treat several important cancer types and to assess the weight of the evidence. Another aim is to determine, through a survey of current practices, whether the use of chemotherapy complies with the scientific evidence presented in the literature. Assessment Strategy Systematic literature review Primary Data Collection Systematic search in MEDLINE through 1998, and in Cancerlit and the Cochrane Library. Important randomized studies published through August 2000 were

Swedish Council on Technology Assessement2001

8359. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer A rapid and systematic review of the clinical effectiveness and cost effectiveness of gemcitabine for the treatment of pancreatic cancer Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could

NIHR HTA programme2001

8360. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer The clinical and cost effectiveness of topotecan for ovarian cancer Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

NIHR HTA programme2001